Breathe Well Live Well
|
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
PR Newswire (press release) Palatin has started discussions with a number of potential development and marketing partners for PL-3994 for acute asthma, which would include the proof-of-concept human trial for asthma using a subcutaneously administered formulation and development … Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript |
View full post on asthma – Google News
|
Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript
Seeking Alpha On the next program, I would like to talk about is PL-3994, our natriuretic peptide receptor agonist in development as a treatment for acute exacerbations of asthma. Acute exacerbations of asthma, also called acute severe asthma, is an ongoing asthma … Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results |
View full post on asthma – Google News
|
CSIR scientists develop new technologies for asthma, diabetic foot
pharmabiz.com The Council of Scientific and Industrial Research (CSIR) has developed two novel technologies in the areas of asthma and diabetes. One is a diagnostic tool for asthmatics and the other is a footwear for lowering the risk of diabetic foot complications. … |
View full post on asthma – Google News
|
FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for …
AUTO-MOBI.info (press release) "We are excited about the prospect of advancing PL-3994 into a Phase 2A human trial to treat asthma patients," stated Dr. Carl Spana, Palatin's Chief Executive Officer. "Existing therapies for acute exacerbations of asthma in patients unresponsive to … |
View full post on asthma – Google News
|
FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for …
DigitalJournal.com (press release) "We are excited about the prospect of advancing PL-3994 into a Phase 2A human trial to treat asthma patients," stated Dr. Carl Spana, Palatin's Chief Executive Officer. "Existing therapies for acute exacerbations of asthma in patients unresponsive to … |
View full post on asthma – Google News
|
FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for …
PR Newswire (press release) "We are excited about the prospect of advancing PL-3994 into a Phase 2A human trial to treat asthma patients," stated Dr. Carl Spana, Palatin's Chief Executive Officer. "Existing therapies for acute exacerbations of asthma in patients unresponsive to … |
View full post on asthma – Google News